N
EVH icon

Natixis’s Evolent Health EVH Stock Holding History

Natixis’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$385K Sell
71,000
-2,100
-3% -$8.05K ﹤0.01% 873
2026
Q1 		$167K Hold
73,100
– – ﹤0.01% 923
2025
Q4 		$292K Hold
73,100
– – ﹤0.01% 902
2025
Q3 		$618K Hold
73,100
– – ﹤0.01% 753
2025
Q2 		$823K Hold
73,100
– – ﹤0.01% 645
2025
Q1 		$692K Buy
+73,100
New +$738K ﹤0.01% 622
2024
Q4 		– Sell
-73,101
Closed -$2.07M – 1094
2024
Q3 		$2.07M Buy
+73,101
New +$1.88M 0.01% 429
2024
Q2 		– Sell
-40,492
Closed -$1.33M – 1049
2024
Q1 		$1.33M Buy
+40,492
New +$1.29M 0.01% 487
2023
Q4 		– Sell
-15,157
Closed -$413K – 1083
2023
Q3 		$413K Buy
+15,157
New +$421K ﹤0.01% 638
2023
Q2 		– Sell
-2,611
Closed -$84.7K – 1057
2023
Q1 		$84.7K Sell
2,611
-20,000
-88% -$632K ﹤0.01% 798
2022
Q4 		$635K Buy
+22,611
New +$648K ﹤0.01% 687
2022
Q2 		– Sell
-7,059
Closed -$228K – 1218
2022
Q1 		$228K Sell
7,059
-163
-2% -$4.27K ﹤0.01% 1096
2021
Q4 		$200K Sell
7,222
-1,822
-20% -$52.3K ﹤0.01% 1177
2021
Q3 		$280K Buy
+9,044
New +$217K ﹤0.01% 1101
2020
Q3 		– Sell
-10,072
Closed -$72K – 798
2020
Q2 		$72K Buy
+10,072
New +$67.5K ﹤0.01% 713
2020
Q1 		– Sell
-45,437
Closed -$413K – 755
2019
Q4 		$413K Sell
45,437
-2,068
-4% -$16.8K ﹤0.01% 729
2019
Q3 		$342K Sell
47,505
-1,442
-3% -$10.3K ﹤0.01% 716
2019
Q2 		$389K Buy
48,947
+33,963
+227% +$402K ﹤0.01% 636
2019
Q1 		$187K Buy
14,984
+4,639
+45% +$73.4K ﹤0.01% 775
2018
Q4 		$206K Buy
+10,345
New +$239K ﹤0.01% 654
2018
Q3 		– Sell
-16,870
Closed -$355K – 863
2018
Q2 		$355K Buy
+16,870
New +$319K ﹤0.01% 737

Other funds holding EVH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RF
Rubicon Founders Nashville, Tennessee $196M AUM 53.12% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Natixis's EVH Position: Q2 2026 in Review

Natixis reduced its Evolent Health (EVH) stake by 2.9% in Q2 2026, selling an estimated $8.05K and leaving 71,000 shares worth $385K. The position accounts for ﹤0.01% of the portfolio, ranked #873.

Natixis first reported a position in EVH in Q2 2018 and has held it in 21 quarters since. The position peaked at $2.07M in Q3 2024. 199 funds tracked by Wall St. Rank hold EVH as of Q2 2026.

  • Natixis held 71,000 shares of Evolent Health worth $385K as of Q2 2026.
  • Natixis sold 2,100 Evolent Health shares in Q2 2026, an estimated $8.05K.
  • Evolent Health made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #873 holding.
  • Natixis first reported a position in Evolent Health in Q2 2018 and has held it in 21 quarters since.
  • Natixis's Evolent Health position peaked at $2.07M in Q3 2024.
  • 199 funds tracked by Wall St. Rank held Evolent Health as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.